Affordable Access

Review of frovatriptan in the treatment of migraine

Authors
Journal
Neuropsychiatric Disease and Treatment
1176-6328
Publisher
Dove Medical Press
Publication Date
Keywords
  • Expert Opinion

Abstract

Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine.

There are no comments yet on this publication. Be the first to share your thoughts.